Infinity Development's Fiscal H1 Profit Slips 14%

FINWIRES Analysis

A 14% profit decline on only a 1.9% revenue dip signals margin compression, implying cost pressure rather than weakening demand drove the result. Maintaining a meaningful interim dividend despite softer earnings suggests management confidence in cash generation or a commitment to payout stability. For a chemical name, input-cost and pricing dynamics are the variables to track next.

Key Takeaways

Profit fell faster than revenue, squeezing margins

Dividend held despite softer earnings

Input costs are the key swing factor

Infinity Development (HKG:0640) recorded an attributable profit of HK$48.8 million in the fiscal first half, down 14% from HK$56.6 million a year prior, according to the company's interim report posted with the Hong Kong bourse Monday.

Basic earnings per share in the six months ended March 31 slipped to HK$0.1602 from HK$0.201 in the corresponding period of the previous year.

Revenue slipped 1.9% to HK$401.5 million in the interim period from HK$409.3 million in the year-ago period.

The chemical company declared an interim dividend of HK$0.079 per ordinary share for the half-year, payable June 18 to shareholders of record on June 8.

Singapore Regulator to Streamline 'Single Family Office' Framework

The Monetary Authority of Singapore has revised its "single family office" (SFOs) framework to streamline the process for SFOs to establish operations in Singapore, according to a MAS release.An SFO in Singapore is a privately held corporate entity set up by one "ultra-high-net-worth" family to manage assets, investments, and wealth of a single family.The registration protocols have been simplified, effective June 15, with offices required to notify MAS of their operations through a MAS-licensed bank.Annual reporting has been made more straightforward for SFOs, with information on total assets under management and the name of its bank.

^STI

Klevo Rewards Plans Stablecoin Trial Launch by June 30; Shares Fall 4%

Klevo Rewards (ASX:KLV) said it plans to launch a trial of its KLVAUD Australian dollar-backed stablecoin by June 30, according to a Monday filing with the Australian bourse.The company's Fly Wallet subsidiary received legal advice indicating that the stablecoin may qualify as an eligible stablecoin under the current regulatory framework, subject to conditions, per the filing.KLVAUD is planned to be fully backed one-to-one by Australian dollars held in segregated reserve accounts, and aims to support Fly Wallet's broader payments system, the company said.Klevo Rewards shares fell 4% in recent Monday trade.

ASX:KLV

Bio-Thera Solutions Gets Europe's Results on On-Site Inspection

Bio-Thera Solutions (SHA:688177) received the results of the European Union's inspection of its Yonghe manufacturing facility, according to a Shanghai bourse filing on Monday.The French National Agency for the Safety of Medicines and Health Products conducted an inspection on the site between Feb. 4 and Feb. 12.The European Medicines Agency handed a GMP or good manufacturing practice certificate to the company after the factory's drug substance operations passed regulatory standards. However, the regulator found deficiencies in the deviation management measures for the finished formulation of the drugs.

SHA:688177